enGene Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
NMIBC treatment is shifting from radical surgery to more tolerable, effective therapies, with detalimogene showing strong efficacy and ease of use for community urologists. Key data updates are expected in Q2 and later this year, supporting a potential 2027 approval.
-
Detalimogene, a non-viral gene therapy for NMIBC, is advancing through pivotal trials with strong regulatory support and a focus on community urologists. The product's ease of use, competitive efficacy, and favorable tolerability are expected to drive adoption as the market shifts toward sequencing therapies.
-
Major protocol amendments and improved execution have driven higher response rates in the pivotal cohort, with 12-month data expected later this year. Regulatory engagement is strong, aided by RMAT and CDRP designations, and the product is positioned for broad adoption in community urology practices due to its ease of use and favorable economics.
-
Detalimogene voraplasmid is advancing as a non-viral gene therapy for NMIBC, showing strong efficacy and tolerability in pivotal trials, with a six-month CR rate of 62%. The product offers significant advantages in ease of use, manufacturing, and cost, with a BLA filing planned for late 2024 and potential launch in 2027.
-
Detalimogene is positioned for strong adoption in community urology due to its efficacy, best-in-class tolerability, and ease of use. The pivotal LEGEND study is fully enrolled, with top-line data and regulatory filing expected in the second half of the year, supported by robust FDA engagement and a flexible pricing strategy.
Fiscal Year 2025
-
A novel non-viral gene therapy platform is advancing a lead product for NMIBC, showing strong efficacy, safety, and ease of use in clinical trials. Regulatory designations and protocol improvements have enhanced outcomes, with a data update expected in 2026 and a launch targeted for 2027.
-
Detalimogene voraplasmid, a non-viral gene therapy for NMIBC, shows strong efficacy and tolerability, with a six-month CR rate of 62% and low adverse events. Positioned for community urologists, it offers simple logistics and is on track for regulatory filing next year.
-
Non-viral gene therapy for NMIBC shows a 63% complete response rate and strong tolerability, matching or exceeding other approved products. Its ease of use and integration into community urology practices, along with a robust manufacturing and IP position, support its competitive outlook.
-
Datolimogene hayemab shows strong efficacy and best-in-class tolerability in NMIBC, with pivotal trial enrollment completed and protocol amendments improving outcomes. Manufacturing and financial positions are robust, supporting U.S. commercialization and further pipeline expansion.
-
Detalimogene's amended LEGEND study protocol led to a 63% anytime and 62% six-month CR rate in high-risk BCG unresponsive NMIBC, with a strong safety and tolerability profile. Ease of use and minimal operational burden make it attractive for community practices. Most 12-month data will mature in late 2026.
-
The company highlighted its non-viral gene therapy platform and lead asset for NMIBC, reporting strong efficacy and tolerability data. Protocol changes in the pivotal study aim to further improve outcomes, with additional data and a BLA filing expected in the next year. Manufacturing, financials, and commercial readiness are on track.
-
Protocol changes have aligned the study with standard of care, and target enrollment has been reached, with most patients under the new protocol. Six-month data will be robust, and a BLA submission is planned for the second half of 2026. Efficacy and safety profiles remain strong, with additional cohorts underway.
-
NMIBC remains a significant unmet need, with detalimogene voraplasmid positioned as a best-in-class, non-viral gene therapy offering strong efficacy, high tolerability, and ease of use for community urologists. Key clinical and regulatory milestones are expected through 2027.
-
Emerging therapies are transforming non-muscle invasive bladder cancer care, with Detalimogene offering a non-viral, patient-friendly alternative showing promising efficacy and safety. Protocol changes aim to close efficacy gaps, and operational advantages support broad adoption.
-
enGene presented its lead genetic medicine for NMIBC, highlighting strong efficacy, excellent tolerability, and ease of use. With robust clinical data, scalable manufacturing, and a solid cash position, the company anticipates regulatory filing in 2025 and potential launch in 2027.
-
Detalimogene voraplasmid, a non-viral genetic therapy for NMIBC, shows strong efficacy and tolerability, with a 71% CR rate and minimal adverse events. Positioned for easy use in community urology, the product is advancing toward pivotal data and potential approval in 2027.
-
The conference highlighted a robust genetic medicine platform and a lead product showing strong efficacy and tolerability in NMIBC, with pivotal trial enrollment on track and regulatory clarity in the U.S. Expansion into global markets and additional indications is planned, with a focus on community-based care and future platform applications.
-
NMIBC care is rapidly shifting toward medical therapies, with detalimogene voraplasmid positioned as a practical, non-viral genetic medicine offering strong preliminary efficacy and safety. Protocol enhancements and upcoming data updates are expected to further strengthen its competitive profile.
Fiscal Year 2024
-
The conference highlighted detalimogene's strong efficacy, favorable safety, and ease of use for NMIBC, especially in community clinics. Interim LEGEND data showed a 71% response rate, and protocol changes aim to improve outcomes. Regulatory alignment and a solid cash runway support ongoing development.
-
The summit highlighted a large, growing NMIBC market and detailed the strong efficacy and safety profile of detalimogene voraplasmid, a non-viral gene therapy in pivotal trials. Protocol changes and new study cohorts aim to further improve outcomes and support a BLA filing by mid-2026.
-
Detalimogene, a non-viral gene therapy for non-muscle invasive bladder cancer, is showing strong efficacy and tolerability in pivotal trials, with protocol amendments expected to further improve outcomes. Regulatory filing is targeted for mid-2026, and commercial plans include both U.S. and global markets.
-
A novel non-viral gene therapy for NMIBC shows strong clinical activity, safety, and ease of use, targeting a large and growing market with significant unmet needs. Regulatory guidance supports a streamlined approval path, with a BLA filing expected in 2026 and expansion into additional patient cohorts underway.
-
A non-viral gene therapy for NMIBC is advancing through a pivotal global study, aiming for a BLA filing in mid-2026. The product offers strong efficacy, excellent tolerability, and practical use, targeting a rapidly expanding market and positioning as a first-choice therapy.
-
The session highlighted a novel non-viral gene therapy in pivotal trials for NMIBC, emphasizing its ease of use, scalable manufacturing, and strong fit for community urology. Preliminary results are expected soon, with a regulatory path supported by recent FDA guidance.
-
A proprietary non-viral platform enables scalable, low-cost genetic medicine delivery, with EG-70 showing strong efficacy and safety in high-risk NMIBC. Interim phase II data is expected mid-2024, with a BLA submission planned for 2026.